Pretreatment lymphopenia, poor performance status, and early courses of therapy are risk factors for severe bacterial infection in patients with multiple myeloma during treatment with bortezomib-based regimens

Shin Young Hyun, Sang Hoon Han, Soo Jeong Kim, Ji Eun Jang, Yundeok Kim, Hyunsoo Cho, Jung Yeon Lee, June Won Cheong, Yoo Hong Min, Jae Woo Song, Jin Seok Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The aim of this study was to identify the risk factors associated with severe bacterial infection (SBI) in multiple myeloma (MM) patients during treatment with bortezomibbased regimens. A total of 98 patients with MM were evaluated during 427 treatment courses. SBI occurred in 57.1% (56/98) of the patients and during 19.0% (81/427) of the treatment courses. In the multivariate analysis for the factors associated with the development of SBI in each treatment course, poor performance status (Eastern Cooperative Oncology Group ≥ 2, P < 0.001), early course of therapy (≤ 2 courses, P < 0.001), and pretreatment lymphopenia (absolute lymphocyte count < 1.0 × 109/L, P = 0.043) were confirmed as independent risk factors. The probability of developing SBI were 5.1%, 14.9%, 23.9%, and 59.5% in courses with 0, 1, 2, and 3 risk factors, respectively (P < 0.001). In conclusion, we identified three pretreatment risk factors associated with SBI in each course of bortezomib treatment. Therefore, MM patients with these risk factors should be more closely monitored for the development of SBI during bortezomib-based treatment.

Original languageEnglish
Pages (from-to)510-518
Number of pages9
JournalJournal of Korean medical science
Volume31
Issue number4
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Lymphopenia
Secondary Prevention
Multiple Myeloma
Bacterial Infections
Therapeutics
Lymphocyte Count
Bortezomib
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Hyun, Shin Young ; Han, Sang Hoon ; Kim, Soo Jeong ; Jang, Ji Eun ; Kim, Yundeok ; Cho, Hyunsoo ; Lee, Jung Yeon ; Cheong, June Won ; Min, Yoo Hong ; Song, Jae Woo ; Kim, Jin Seok. / Pretreatment lymphopenia, poor performance status, and early courses of therapy are risk factors for severe bacterial infection in patients with multiple myeloma during treatment with bortezomib-based regimens. In: Journal of Korean medical science. 2016 ; Vol. 31, No. 4. pp. 510-518.
@article{81d3e690e1b94ffb98a76391cb1b943f,
title = "Pretreatment lymphopenia, poor performance status, and early courses of therapy are risk factors for severe bacterial infection in patients with multiple myeloma during treatment with bortezomib-based regimens",
abstract = "The aim of this study was to identify the risk factors associated with severe bacterial infection (SBI) in multiple myeloma (MM) patients during treatment with bortezomibbased regimens. A total of 98 patients with MM were evaluated during 427 treatment courses. SBI occurred in 57.1{\%} (56/98) of the patients and during 19.0{\%} (81/427) of the treatment courses. In the multivariate analysis for the factors associated with the development of SBI in each treatment course, poor performance status (Eastern Cooperative Oncology Group ≥ 2, P < 0.001), early course of therapy (≤ 2 courses, P < 0.001), and pretreatment lymphopenia (absolute lymphocyte count < 1.0 × 109/L, P = 0.043) were confirmed as independent risk factors. The probability of developing SBI were 5.1{\%}, 14.9{\%}, 23.9{\%}, and 59.5{\%} in courses with 0, 1, 2, and 3 risk factors, respectively (P < 0.001). In conclusion, we identified three pretreatment risk factors associated with SBI in each course of bortezomib treatment. Therefore, MM patients with these risk factors should be more closely monitored for the development of SBI during bortezomib-based treatment.",
author = "Hyun, {Shin Young} and Han, {Sang Hoon} and Kim, {Soo Jeong} and Jang, {Ji Eun} and Yundeok Kim and Hyunsoo Cho and Lee, {Jung Yeon} and Cheong, {June Won} and Min, {Yoo Hong} and Song, {Jae Woo} and Kim, {Jin Seok}",
year = "2016",
month = "1",
day = "1",
doi = "10.3346/jkms.2016.31.4.510",
language = "English",
volume = "31",
pages = "510--518",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "4",

}

Pretreatment lymphopenia, poor performance status, and early courses of therapy are risk factors for severe bacterial infection in patients with multiple myeloma during treatment with bortezomib-based regimens. / Hyun, Shin Young; Han, Sang Hoon; Kim, Soo Jeong; Jang, Ji Eun; Kim, Yundeok; Cho, Hyunsoo; Lee, Jung Yeon; Cheong, June Won; Min, Yoo Hong; Song, Jae Woo; Kim, Jin Seok.

In: Journal of Korean medical science, Vol. 31, No. 4, 01.01.2016, p. 510-518.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pretreatment lymphopenia, poor performance status, and early courses of therapy are risk factors for severe bacterial infection in patients with multiple myeloma during treatment with bortezomib-based regimens

AU - Hyun, Shin Young

AU - Han, Sang Hoon

AU - Kim, Soo Jeong

AU - Jang, Ji Eun

AU - Kim, Yundeok

AU - Cho, Hyunsoo

AU - Lee, Jung Yeon

AU - Cheong, June Won

AU - Min, Yoo Hong

AU - Song, Jae Woo

AU - Kim, Jin Seok

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The aim of this study was to identify the risk factors associated with severe bacterial infection (SBI) in multiple myeloma (MM) patients during treatment with bortezomibbased regimens. A total of 98 patients with MM were evaluated during 427 treatment courses. SBI occurred in 57.1% (56/98) of the patients and during 19.0% (81/427) of the treatment courses. In the multivariate analysis for the factors associated with the development of SBI in each treatment course, poor performance status (Eastern Cooperative Oncology Group ≥ 2, P < 0.001), early course of therapy (≤ 2 courses, P < 0.001), and pretreatment lymphopenia (absolute lymphocyte count < 1.0 × 109/L, P = 0.043) were confirmed as independent risk factors. The probability of developing SBI were 5.1%, 14.9%, 23.9%, and 59.5% in courses with 0, 1, 2, and 3 risk factors, respectively (P < 0.001). In conclusion, we identified three pretreatment risk factors associated with SBI in each course of bortezomib treatment. Therefore, MM patients with these risk factors should be more closely monitored for the development of SBI during bortezomib-based treatment.

AB - The aim of this study was to identify the risk factors associated with severe bacterial infection (SBI) in multiple myeloma (MM) patients during treatment with bortezomibbased regimens. A total of 98 patients with MM were evaluated during 427 treatment courses. SBI occurred in 57.1% (56/98) of the patients and during 19.0% (81/427) of the treatment courses. In the multivariate analysis for the factors associated with the development of SBI in each treatment course, poor performance status (Eastern Cooperative Oncology Group ≥ 2, P < 0.001), early course of therapy (≤ 2 courses, P < 0.001), and pretreatment lymphopenia (absolute lymphocyte count < 1.0 × 109/L, P = 0.043) were confirmed as independent risk factors. The probability of developing SBI were 5.1%, 14.9%, 23.9%, and 59.5% in courses with 0, 1, 2, and 3 risk factors, respectively (P < 0.001). In conclusion, we identified three pretreatment risk factors associated with SBI in each course of bortezomib treatment. Therefore, MM patients with these risk factors should be more closely monitored for the development of SBI during bortezomib-based treatment.

UR - http://www.scopus.com/inward/record.url?scp=84961901667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961901667&partnerID=8YFLogxK

U2 - 10.3346/jkms.2016.31.4.510

DO - 10.3346/jkms.2016.31.4.510

M3 - Article

C2 - 27051233

AN - SCOPUS:84961901667

VL - 31

SP - 510

EP - 518

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 4

ER -